Fevzi F. Yalniz

Fevzi F. Yalniz, MD, is an Assistant Professor in the Department of Internal Medicine, Division of Hematology and Blood Marrow Transplantation at the University of Kentucky College of Medicine. He is a key clinical and research faculty member at the UK Markey Cancer Center, specializing in hematologic malignancies and advanced cellular therapies.

His education includes an M.D. from Hacettepe University, Turkey, followed by residency in Internal Medicine at Yeditepe University, and fellowships in Hematology, Stem Cell Transplantation, and Leukemia at Istanbul University, Mayo Clinic, and MD Anderson Cancer Center.

• Hacettepe University, Ankara, Turkey – M.D.
• Yeditepe University, Istanbul, Turkey – Internal Medicine Residency
• Istanbul University Cerrahpasa Faculty of Medicine – Hematology Fellowship
• Mayo Clinic, Rochester – Postdoctoral Research Fellowship in Hematology and BMT
• MD Anderson Cancer Center, Houston – Leukemia and Stem Cell Transplantation Fellowships

Dr. Yalniz's research and clinical interests focus on leukemias, lymphomas, myelodysplastic syndromes, multiple myeloma, stem cell transplantation, and CAR T-cell therapy. His work bridges translational research and clinical application, particularly in improving outcomes for patients with relapsed or refractory blood cancers.

The analysis of his recent publications reveals a strong trend in cellular therapies, transplant outcomes, minimal residual disease, and immunotherapy. His work spans clinical trials, real-world data, and meta-analyses, with emphasis on safety, efficacy, and equitable access to cutting-edge treatments.

His notable scientific awards include:

• Conquer Cancer Foundation of ASCO Merit Award
• American Society of Hematology Achievement Award

Dr. Yalniz is actively involved in clinical research and patient care, contributing to national guidelines and advancing therapies for hematologic cancers. He is a member of the American Society of Hematology and the American Society for Transplantation and Cellular Therapy. While no formal advisees are listed, his mentorship likely extends through clinical training and research collaboration. He participates in multicenter trials and leads initiatives in transplant optimization and cellular therapy safety.

He is affiliated with the UK Markey Cancer Center and works within a multidisciplinary team focused on hematologic malignancies, where he contributes to both clinical innovation and education of trainees.